Quirós, L. P., & Ugalde, R. (2019). Analysis of the budgetary impact of alemtuzumab as second-line therapy, compared to natalizumab and fingolimod, in patients previously treated with interferon beta 1b, diagnosed with active relapsing-remitting multiple sclerosis, treated in the Costa Rican social security fund. Global and Regional Health Technology Assessment, 6(1). https://doi.org/10.33393/grhta.2019.467